title: New anthyarrhythmic drugs for atrial fibrillation.
abstract: Atrial fibrillation (AF) is a common arrhythmia associated with increased mortality and morbidity. Different studies have shown no significant difference between rhythm and rate control strategies in terms of mortality. Moreover, the use of antiarrhythmic drugs is afflicted by cardiac and extracardiac toxicity and related costs of hospitalization. Nevertheless, some patients require a rhythm-control strategy and new anti-AF agents are being sought. Only few novel agents showed promising results in term of efficacy and safety. Dronedarone and vernakalant are two of these compounds, respectively introduced for the chronic and acute rhythm control of AF. This article will review pharmacology and clinical evidence on the use of dronedarone and vernakalant and will mention currently investigated new antiarrhythmic drugs.
authors.affiliation: Cardiology & Arrhythmology Clinic, 'Ospedali Riuniti' University Hospital, Marche Polytechnic University, Ancona, Italy.
authors.forename: Maria Vittoria
authors.initials: MV
authors.lastname: Matassini
authors.affiliation: Cardiology & Arrhythmology Clinic, 'Ospedali Riuniti' University Hospital, Marche Polytechnic University, Ancona, Italy.
authors.forename: Federico
authors.initials: F
authors.lastname: Guerra
authors.forename: Lorena
authors.initials: L
authors.lastname: Scappini
authors.affiliation: Cardiology & Arrhythmology Clinic, 'Ospedali Riuniti' University Hospital, Marche Polytechnic University, Ancona, Italy.
authors.forename: Loren
authors.initials: L
authors.lastname: Scappini
authors.affiliation: Cardiology & Arrhythmology Clinic, 'Ospedali Riuniti' University Hospital, Marche Polytechnic University, Ancona, Italy.
authors.forename: Alessia
authors.initials: A
authors.lastname: Urbinati
authors.affiliation: Cardiology & Arrhythmology Clinic, 'Ospedali Riuniti' University Hospital, Marche Polytechnic University, Ancona, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Capucci
mesh_terms: D000638:Amiodarone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000840:Anisoles / Q000494:pharmacology / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D000077764:Dronedarone; D006801:Humans; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use*; D000069458:Ranolazine / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000840:Anisoles; D000889:Anti-Arrhythmia Agents; D011759:Pyrrolidines; C524581:vernakalant; D000069458:Ranolazine; D000077764:Dronedarone; D000638:Amiodarone
keywords: anthyarrhythmic drugs; atrial fibrillation; cardioversion; dronedarone; ranolazine; rate control; rhythm control; vernakalant